GSK Bio
NEWS
MorphoSys AG reports results for the first quarter of 2019.
Celgene Corporation and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in patients with relapsed and refractory multiple myeloma.
In its announcement, GSK said the decision to cut the two programs were made following an analysis of available research results, including interim data from an ongoing Phase I study of the flu vaccine.
Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
The funding will be used to expand the production capacity of key components of the adjuvant system used in several of GSK’s vaccines, including shingles vaccine, Shingrix.
Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
Dr. Revah will join fellow industry panelists at the Cell and Gene Meeting on the Med in Barcelona to discuss strategies for gene therapy manufacturing, on April 23rd
Akorn secured approval for a post-operative eye drop, as well as a generic over-the-counter version of GSK’s Flonase.
JOBS
IN THE PRESS